Trial Profile
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With IL-2 Receptor Antagonist, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Basiliximab; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Registrational; Therapeutic Use
- Acronyms ASSET
- Sponsors Novartis
- 17 Dec 2009 Actual number of patients (229) added as reported by ClinicalTrials.gov record.
- 17 Dec 2009 Actual end date (1 Dec 2007) added as reported by ClinicalTrials.gov
- 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov